Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Has announcements × mCRPC × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 54 Breast Neoplasms 31 Neoplasms 30 Multiple Myeloma 24 Parkinson Disease 4, Autosomal Dominant Lewy Body 22 Recurrence 19 Leukemia, Myeloid, Acute 18 Colorectal Neoplasms 16 Neoplasm Metastasis 15 Leukemia 14 Lymphoma, Non-Hodgkin 14 Melanoma 14 Carcinoma, Renal Cell 13 Leukemia, Lymphocytic, Chronic, B-Cell 13 Lymphoma, Follicular 12 Ovarian Neoplasms 12 Precursor Cell Lymphoblastic Leukemia-Lymphoma 12 Leukemia, Myelogenous, Chronic, BCR-ABL Positive 10 Lung Neoplasms 10 Lymphoma, Large B-Cell, Diffuse 10 Myelodysplastic Syndromes 10 Adenocarcinoma 9 Carcinoma, Hepatocellular 9 Hematologic Neoplasms 9 Urinary Bladder Neoplasms 9 Carcinoma 8 Lymphoma, B-Cell, Marginal Zone 8 Lymphoma, Mantle-Cell 8 Prostatic Neoplasms 8 Small Cell Lung Carcinoma 8

Interventions

talazoparib 1 enzalutamide 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03395197 2026-03-12

TALAPRO-2

Pfizer

Phase 3 Active not recruiting

1,054 enrolled 21 charts 1 FDA

mCRPC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡